In wake of third straight mid-stage set­back, Anap­tys­Bio looks to punt IL-36 drug — even as PhI­II goes on

De­spite a new Phase II flop, Anap­tys­Bio says it re­mains “op­ti­mistic” on its lead drug — it just doesn’t want to be the one tak­ing the drug all the way through.

Anap­tys­Bio had set up a slate of stud­ies for im­si­dolimab, an an­ti­body block­ing IL-36R, and al­ready scrapped two in­di­ca­tions — se­vere pal­mo­plan­tar pus­tu­lo­sis and ac­ne — af­ter the tri­als failed. Its long­time CEO abrupt­ly re­signed af­ter the last tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER